Your browser doesn't support javascript.
loading
Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Huang, Jingjun; Guo, Yongjian; Huang, Wensou; Hong, Xiaotao; Quan, Yi; Lin, Liteng; Zhou, Jingwen; Liang, Licong; Zhang, Yaqin; Zhou, Juan; Cai, Mingyue; Zhu, Kangshun.
Afiliação
  • Huang J; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Guo Y; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Huang W; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Hong X; Department of Interventional Medical Center, Jieyang People's Hospital, Jieyang City, Guangdong Province, People's Republic of China.
  • Quan Y; Department of Oncology Medical Center, The First People's Hospital of Zhaoqing, Zhaoqing City, Guangdong Province, People's Republic of China.
  • Lin L; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Zhou J; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Liang L; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Zhang Y; Department of Radiology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai City, Guangdong Province, People's Republic of China.
  • Zhou J; Department of Pharmacy, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Cai M; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
  • Zhu K; Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
J Hepatocell Carcinoma ; 9: 157-170, 2022.
Article em En | MEDLINE | ID: mdl-35300208
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article